Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage

Summary

Primary Objective: To investigate the effectiveness of intravitreal applications of 0.5 mg Lucentis (ranibizumab) in patients with vitreous hemorrhage due to proliferative diabetic retinopathy. The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to the mean level at Month 3. Secondary Objectives: 1. To assess any differences in mean change in BCVA over time; 2. To assess differences in vitreous transparency (amount of hemorrhage) with fundus angiography exam; 3. To assess any differences in retinopathy severity level according to the Early Treatment Diabetic Retinopathy Study; 4. To correlate the visual outcomes with serum glucose levels.

Timeline

Start

2013-03

Primary completion

2013-09

Completion

2013-12

Drugs

Indications